Sparfloxacin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Acute bacterial exacerbation of chronic bronchitis; Community-acquired pneumonia 100-300 mg/day in 1-2 divided doses.
Dosage Details
Oral
Community-acquired pneumonia, Acute bacterial exacerbation of chronic bronchitis
Adult: 100-300 mg daily, as a single dose or 2 divided doses.
Renal Impairment
Dosage adjustment may be necessary in severe impairment.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity; pregnancy and lactation; children <18 yr.
Special Precautions
History of CNS disorders, pseudomembranous colitis, superinfection, severe renal dysfunction, epilepsy, G6PD deficiency, myasthenia gravis, patients with QT prolongation, uncorrected electrolyte disturbances, bradycardia, or pre-existing cardiac disease. Avoid exposure to strong sunlight or sunlamps during treatment. Discontinue treatment if patients experience tendon pain, inflammation or rupture; subsequent use of fluoroquinolones in these patients is not recommended. Avoid in MRSA infections due to high risk of resistance. Ensure adequate fluid intake to reduce risk of crystalluria.
Adverse Reactions
Diarrhoea, abdominal pain, nausea, vomiting; jaundice, renal failure, elevation of liver enzymes, BUN and creatinine; anaphylactoid reaction, headache, dizziness, convulsions; tremors, myalgia; rhabdomyolysis, thrombocytopenia and eosinophilia.
Potentially Fatal: AV block; anaphylaxis.
Drug Interactions
Cations such as aluminum, magnesium, zinc and iron may reduce the bioavailability of sparfloxacin. May increase the plasma concentrations of theophylline and tizanidine. May enhance the effect of warfarin and glibenclamide. May decrease the renal clearance of methotrexate. Excretion may be reduced by probenecid. May alter serum levels of phenytoin.
Potentially Fatal: Corticosteroids may increase risk of tendon rupture. Increased risk of seizures with NSAIDs. Risk of additive QT prolongation effect when used with class Ia or III antiarrhythmic drugs, astemizole, terfenadine, cisapride, erythromycin, pentamidine, phenothiazines or TCAs.
Action
Description: Sparfloxacin inhibits the supercoiling activity of DNA gyrase which is an enzyme essential for DNA replication thus promoting the breakage of DNA structures. It has activity against S. pneumoniae, S. aureus, H. influenzae, K. pneumoniae, M. catarrhalis and Mycobacterium spp.
Pharmacokinetics:
Absorption: Well absorbed from the GI tract (oral); peak plasma concentrations after 3-6 hr.
Distribution: Widely distributed into tissues including respiratory tissues. Protein-binding: 45%.
Metabolism: Hepatic (by glucuronidation).
Excretion: Excreted in equal amounts in the urine and faeces as unchanged drug and glucuronide metabolites; elimination half-life: 20 hr.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Sparfloxacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in